---
title: "ASC36_35 FDC — Stuff That Spins"
description: "Narrative intelligence for ASC36_35 FDC: 1 tracked articles, claims, and spin patterns across AI and technology coverage."
	canonical: "https://stuffthatspins.com/entities/asc36-35-fdc"
html: "https://stuffthatspins.com/entities/asc36-35-fdc"
json: "https://stuffthatspins.com/entities/asc36-35-fdc.json"
markdown: "https://stuffthatspins.com/entities/asc36-35-fdc.md"
keywords: ["ASC36_35 FDC", "product", "AI", "technology", "spin analysis"]
json_ld: |
  {"@context":"https://schema.org","@graph":[{"@type":"Product","@id":"https://stuffthatspins.com/entities/asc36-35-fdc","name":"ASC36_35 FDC","description":"Narrative intelligence for ASC36_35 FDC across AI and technology coverage.","url":"https://stuffthatspins.com/entities/asc36-35-fdc","identifier":"asc36-35-fdc"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Stuff That Spins","item":"https://stuffthatspins.com/"},{"@type":"ListItem","position":2,"name":"ASC36_35 FDC","item":"https://stuffthatspins.com/entities/asc36-35-fdc"}]},{"@type":"ItemList","name":"Articles about ASC36_35 FDC","itemListElement":[{"@type":"ListItem","position":1,"url":"https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-","name":"Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35"}]},{"@type":"ItemList","name":"Claims involving ASC36_35 FDC","itemListElement":[{"@type":"ListItem","position":1,"item":{"@type":"Claim","text":"ASC36_35 FDC is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR."}}]}]}
---

# ASC36_35 FDC

**Type:** product  
## Related Articles

- [Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35](https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-) — July 6, 2026

## Related Claims

- ASC36_35 FDC is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR.

---
*HTML version: https://stuffthatspins.com/entities/asc36-35-fdc*